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Purpose: To investigate the molecular responses of various genes and proteins re-
lated to disc degeneration upon treatment with cytokines that affect disc-cell pro-
liferation and phenotype in living human intervertebral discs (IVDs). Responsive-
ness to these cytokines according to the degree of disc degeneration was also 
evaluated. Materials and Methods: The disc specimens were classified into two 
groups: group 1 (6 patients) showed mild degeneration of IVDs and group 2 (6 pa-
tients) exhibited severe degeneration of IVDs. Gene expression was analyzed after 
treatment with four cytokines: recombinant human bone morphogenic protein (rh-
BMP-2), transforming growth factor-β (TGF-β), interleukin-1β (IL-1β), and tumor 
necrosis factor-α (TNF-α). Molecular responses were assessed after exposure of 
cells from the IVD specimens to these cytokines via real-time polymerase chain 
reaction and immunofluorescence staining. Results: mRNA gene expression was 
significantly greater for aggrecan, type I collagen, type II collagen, alkaline phos-
phatase, osteocalcin, and Sox9 in group 1 than mRNA gene expression in group 2, 
when the samples were not treated with cytokines. Analysis of mRNA levels for 
these molecules after morphogen treatment revealed significant increases in both 
groups, which were much higher in group 1 than in group 2. The average number 
of IVD cells that were immunofluorescence stained positive for alkaline phospha-
tase increased after treatment with rhBMP-2 and TGF-β in group 1. Conclusion: 
The biologic responsiveness to treatment of rhBMP-2, TGF-β, TNF-α, and IL-1β in 
the degenerative living human IVD can be different according to the degree of de-
generation of the IVD.
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INTRODUCTION
Degeneration of the intervertebral disc (IVD) is a natural aging process. Healthy 
IVDs exhibit high water content in the nucleus pulposus (NP), as its matrix is rich 
in large aggregating proteoglycans.1,2 With degeneration, there is a progressive loss 
of the proteoglycan matrix, which normally functions to retain water. This causes 
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of IVDs to treatment with cytokines. Nevertheless, the bio-
logic responsiveness living human IVDs to cytokine treat-
ment in relation to degeneration grade has not been studied.
Accordingly, the objective of this study was to investi-
gate the molecular responses of various genes and proteins 
related to disc degeneration upon treatment with cytokines 
known to influence disc-cell proliferation and phenotype in 
living human IVD cells obtained from patients undergoing 
discectomy. As well, responsiveness to these cytokines was 
assessed according to the degree of degeneration in living 
human IVD cells.
MATERIALS AND METHODS
Study design
Living human disc specimens were obtained from 12 pa-
tients who underwent discectomy for degenerative lumbar 
disc herniation and who were unresponsive to conservative 
therapy. Exclusion criteria included infection, metabolic 
bone disease and neoplastic disease. MRI (Magneton Vision 
1.5T, Siemens, Erlangen, Germany) was performed for all 
patients. The PACS software and PACS workstation (Cen-
tricity 2.0, General Electrics Medical Systems, Milwaukee, 
WI, USA) was used for review by an independent neurosur-
geon and neuroradiologist. Disc degeneration was graded on 
routine T2-weighted MRI images using the Pfirrmann grad-
ing system. The disc specimens were classified into two 
groups: patients in group 1 (6 patients) exhibited mild de-
generation of IVDs (Grade II and III), while patients in 
group 2 (6 patients) showed severe degeneration of IVDs 
(Grade IV and V). This study was approved by the Institu-
tional Review Board of our institute (No. 6-2008-0290).
Isolation of disc cells and culture  
Unless otherwise stated, all reagents were purchased from 
GibcoBRL (Grand Island, NY, USA). Intervertebral disc ma-
terials were collected from patients during discectomy. To 
make the samples homologous, disc materials were acquired 
from the nucleus pulposus and not the annulus. Tissues from 
each disc were dissected into small pieces and incubated (5% 
CO2, 95% room air at 37°C) in Dulbecco’s Modified Eagle 
Medium and Ham’s F-12 (DMEM/F-12) media. To isolate 
the cells, disc tissue was digested in DMEM/F-12 media 
with 0.2% protease (Sigma Chemical, St. Louis, MO, USA) 
for 1 hour, followed by 0.025% collagenase (Sigma Chemi-
cal) for 12 hours. Cells from less than two passages were 
dehydration and desiccation within the NP, and the IVD be-
comes a more fibrotic and less cartilaginous structure.3-6 
Degeneration of IVDs is clinically associated with lower 
back pain and other important diseases of the spine. Treat-
ment options range from pain management to invasive pro-
cedures, such as discectomy, intradiscal electrothermal 
therapy, fusion, and spinal arthroplasty. However, these op-
tions address the clinical symptoms of degeneration of the 
IVD rather than targeting the pathophysiological pathways 
involved in the degenerative process. 
Genetic, mechanical, and biologic factors are widely re-
garded as important contributors to the degenerative pro-
cess.7-14 To better characterize the degenerative process and 
to prevent or reverse degenerative changes in the disc ma-
trix by altering disc matrix metabolism, many investigators 
have conducted biological experiments and attempted treat-
ment of disc degeneration utilizing cellular components, 
matrix-derivatives, and molecules known to influence disc 
cell metabolism and phenotype.15-19 There are at least four 
different classes of molecules that are currently being in-
vestigated for disc therapy: anti-catabolics, mitogens, mor-
phogens, and intracellular regulators. All of these molecules 
have some in vitro data supporting their use; however, few 
have been tested in animal models of disc degeneration to 
verify the biological mechanisms of each molecule. There 
is no clinically proven biological therapy for degeneration 
of human IVDs.7,9-11,15,16,19-26 The results of biological thera-
pies may differ according to the therapeutic modalities used 
and the degree of degeneration, both of which are further 
related to the chemical composition and histologic changes 
of the IVD.25,27-30 
The aging process changes the expression levels and spa-
tial distribution of transforming growth factor (TGF) and 
bone morphogenic protein (BMP) molecules and recep-
tors.12,31 Okuda, et al.13 supported this notion by demonstrat-
ing that the responsiveness of intervertebral cells to insulin-
likegrowth factor-1 (IGF-1) and TGF-β decreases with 
advancing age in rabbit disc cells. Thompson, et al.32 were 
the first to demonstrate that exogenous administration of a 
growth factor, TGF-1, can significantly increase proteogly-
can synthesis in NP cells in vitro. This prompted further in-
vestigation into other growth factors such as IGF-1, BMP-2, 
and BMP-7, all of which have been shown to enhance the 
anabolic functions of IVD cells by up-regulating proteogly-
can synthesis.33,34 Degeneration of IVDs may reflect molec-
ular biologic changes in the IVD with age, and the degree 
of IVD degeneration may be influence the responsiveness 
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USA), IL-1β 10 ng/mL (Invitrogen) and TNF-α 10 ng/mL 
(Invitrogen) for 6 days. On day 3, the culture media were 
changed with the same concentrations of rhBMP-2, TGF-β, 
IL-1β, and TNF-α in each well. 
 
Real-time polymerase chain reaction (PCR) assay
An ABI Prism 7300 (Applied Biosystemz, Foster City, CA, 
USA) was used to detect SYBR Green fluorescent dye in-
corporated in double-stranded DNA. A 20 µL reaction vol-
ume included 25 ng of cDNA from real-time polymerase 
chain reaction (RT-PCR) and 5 pmole of each primer (ag-
grecan, alkaline phosphatase, type I collagen, type II colla-
gen, osteocalcin, and Sox9). Forty RT-PCR cycles were 
performed for denaturation (95°C for 30 seconds), anneal-
ing, and elongation (60°C for 60 seconds). To confirm am-
plification specificity, PCR products were subjected to a 
melting curve analysis. Threshold cycles (Ct) of aggrecan, 
alkaline phosphatase, type I collagen, type II collagen, os-
teocalcin, and Sox9 were standardized according to GAP-
DH. The mRNA expression of group 1 was compared to 
group 2 and reported as a ratio. 
Immunofluorescence staining with antibodies
Each cell sample (3×104 cells/well) was grown as a mono-
layer culture in the DMEM/F-12 culture media containing 
1% FBS, 10 U/mL penicillin, 10 g/mL streptomycin, 0.2 
mmol/L L-glutamine, and 5 μg/mL vitamin C for 3 days in 
the incubator (5% CO2, 95% room air at 37°C). The cul-
tured cells were fixed with 100% EtOH and then washed 
with 10 mM PBS solution (Sigma, St. Louis, MO, USA). 
used for each experiment. Each sample of disc cells (2×105 
cells/well) was grown as a monolayer culture for 6 days in 
DMEM/F-12 media with 10% fetal bovine serum (FBS), 
10 U/mL penicillin, 10 g/mL streptomycin, and 0.2 mmol/L 
L-glutamine. After 6 days, mRNA expression of aggrecan, 
type I collagen, type II collagen, Sox9, alkaline phospha-
tase, osteocalcin, and glyceraldehydes phosphate dehydro-
genase (GAPDH) was assayed using the complete mRNA 
sequence from the National Center for Biotechnology In-
formation. Forward and reverse primer sequences of aggre-
can, type I collagen, type II collagen, Sox9, osteocalcin, 
and alkaline phosphatase are listed in Table 1. 
Treatment with cytokines
Samples from each experimental group were also cultured in 
a chamber slide in an incubator (5% CO2, 95% room air at 
37°C) at 3×104 cells/chamber. When the cell culture became 
confluent, the media was replaced with DMEM/F-12 media 
containing 1% FBS+10 U/mL penicillin, 10 g/mL strepto-
mycin, 0.2 mmol/l L-glutamine, and 5 μg/mL vitamin C. The 
gene expression after treatment with four cytokines was an-
alyzed. Recombinant human bone morphogenic protein-2 
(rhBMP-2) and TGF-β were used as morphogens for the 
disc cells. Interleukin-1β (IL-1β) and tumor necrosis factor-α 
(TNF-α) were treated as inflammatory mediators implicat-
ed in disc degeneration. mRNA expression from disc cell 
culture without cytokines was used as a baseline control 
value. Disc cells were cultured in monolayer and treated 
with rhBMP-2 100 ng/mL (R&D System, Minneapolis, 
MN, USA), TGF-β 10 ng/mL (Invitrogen, Carlsbad, CA, 
Table 1. Primer-Sequence for Real-Time PCR
Primer nucleotide sequence (5’-3’)
Aggrecan
Forward CTGCTTCCGAGGCATTTCAG
Reverse CTTGGGTCACGATCCACTCC
Type I collagen
Forward GTCGAGGGCCAAGACGAAG
Reverse CAGATCACGTCATCGCACAAC
Type II collagen
Forward GGTCTTGGTGGAAACTTTGCT
Reverse GGTCCTTGCATTACTCCCAAC
Sox9
Forward AGCGAACGCACATCAAGAC
Reverse GCTGTAGTGTGGGAGGTTGAA
Alkaline phosphatase
Forward ATGGGATGGGTGTCTCCACA
Reverse CCACGAAGGGGAACTTGTC
Osteocalcin
Forward CACTCCTCGCCCTATTGGC
Reverse CCCTCCTGCTTGGACACAAAG
GAPDH*
Forward ATGGGGAAGGTGAAGGTCG
Reverse GGGGTCATTGATGGCAACAATA
PCR, polymerase chain reaction; GAPDH, glyceraldehydes phosphate dehydrogenase.
*GAPDH was used as a house keeping gene.
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RESULTS
 
Degeneration of IVD
Using the Pfirrmann grading system, the discs of 12 pa-
tients were classified into two groups: group 1 (6 patients) 
contained mildly degenerated discs (grade II; 3 patients and 
grade III; 3 patients) and group 2 (6 patients) contained se-
verely degenerated discs (grade IV; 2 patients and grade V; 4 
patients). The mean patient age in group 2 (59.9±13.9 year) 
was significantly higher than group 1 (43.1±13.3 year) 
(p<0.05).
Quantitation of mRNA levels
The mRNA levels of genes specific for aggrecan, type I 
collagen, type II collagen, alkaline phosphatase, osteocal-
cin, and Sox9 which were produced from forty RT-PCR cy-
cles were analyzed. 
mRNA gene expression in group 1 (mild degenerative 
IVD) was significantly greater for aggrecan, type I colla-
gen, type II collagen, alkaline phosphatase, osteocalcin, and 
Sox9 than the mRNA gene expressions thereof in group 2 
(severe degenerative IVD). The differences in mRNA gene 
expression between the two groups for aggrecan, type I col-
lagen, type II collagen, alkaline phosphatase, and Sox9 
were all statistically significant (Fig. 1).
mRNA levels of aggrecan, type I collagen, type II 
collagen, alkaline phosphatase, osteocalcin, and Sox9 
after cytokine treatment
In order to confirm the response to cytokines, the mRNA 
levels of these genes without cytokine treatment were used 
as a control. The values of each mRNA level of these genes 
were compared as a ratio with their mRNA levels without 
cytokine treatment. 
The mRNA levels of aggrecan after treatment with mor-
phogens increased by 5.46-fold with rhBMP-2 and 3.55-
fold with TGF-β in group 1, and increased by 2.67-fold 
with rhBMP-2 and 2.30-fold with TGF-β in group 2. The 
mRNA expression of aggrecan after treatment with inflam-
matory mediators decreased by 0.48-fold with TNF-α and 
0.61-fold with IL-1β in group 1 and decreased by 0.65-fold 
with TNF-α and 0.51-fold with IL-1β in group 2. The re-
sponse to rhBMP-2 in group 1 was greater by 2.03-fold 
than that of group 2 (p<0.05). However, the response to 
others cytokines showed no statistical difference between 
the two groups (Fig. 2A).
Monoclonal anti-aggrecan, anti-alkaline phosphatase, anti-
type I collagen, anti-type II collagen, anti-osteocalcin, and 
anti-Sox9 were applied at 4°C overnight. After washing, 
secondary antibody conjugated with fluorescein isothiocya-
nate (FITC) was applied to the wells (room temperature, 2 
hours). The immunoreactivity of the IVD cells for rhBMP-2 
and TGF-β was analyzed to examine the chondrogenic ac-
tivity. The wells were then rinsed, mounted and photo-
graphed with a fluorescence photomicroscope (NIKON mi-
crophot-SA, Kogaku, Japan). For immunofluorescence, 
fluoroch-romes on the sections were exited using a 510 nm 
emission filter for a green fluorescent protein, and a 580 nm 
emission filter for a secondary antibody with FITC. We 
counted the average number of immunofluorescence-posi-
tive-stained IVD cells for anti-aggrecan, anti-alkaline phos-
phatase, anti-type I collagen, anti-type II collagen, anti-os-
teocalcin, and anti-Sox9 in both group 1 and group 2. Five 
out of nine wells were scanned using light microscopy. The 
number of immunofluorescence-positive-stained IVD cells 
in each of the five wells was tabulated and extrapolated to 
the total of nine wells. The average number of immunofluo-
rescence-positive-stained IVD cells was compared as the 
average number of cells without cytokine treatment and ex-
pressed as a ratio.
Statistical analysis
Student’s t-test and the Wilcoxon signed-rank test were used 
for intergroup comparisons. Values are reported as mean± 
SD. All values of p<0.05 were considered statistically sig-
nificant. All analyses were carried out using SPSS, version 
12.0 (SPSS Inc., Chicago, IL, USA).
Fig. 1. mRNA gene expression in group 1 (mild degenerative IVD) was sig-
nificantly greater for aggrecan, type I collagen, type II collagen, alkaline 
phosphatase, osteocalcin, and Sox9 than mRNA gene expression in group 
2 (severe degenerative IVD). *p<0.01. **p<0.05. IVD, intervertebral disc.
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morphogens increased by 4.35-fold with rhBMP-2 and 
3.87-fold with TGF-β in group 1, and increased by 1.84-
fold with rhBMP-2 and 2.54-fold with TGF-β in group 2. 
The mRNA expression for type I collagen after treatment 
with inflammatory mediators decreased by 0.84-fold with 
TNF-α and 0.75-fold with IL-1β in group 1, and decreased 
by 0.70-fold with TNF-α and 0.77-fold with IL-1β in group 
2. The response to all cytokines showed no statistical differ-
ence between the two groups (Fig. 2C).
The mRNA levels of type II collagen after treatment with 
morphogens increased by 3.92-fold with rhBMP-2 and 
3.59-fold with TGF-β in group 1, and increased by 2.51-
fold with rhBMP-2 and 2.93-fold with TGF-β in group 2. 
The mRNA expression for type II collagen after treatment 
The mRNA levels of alkaline phosphatase after treatment 
with morphogens increased by 4.82-fold with rhBMP-2 and 
4.63-fold with TGF-β in group 1, and increased by 2.62-fold 
with rhBMP-2 and 2.31-fold with TGF-β in group 2. The 
mRNA expression of alkaline phosphatase after treatment 
with inflammatory mediators decreased by 0.59-fold with 
TNF-α and 0.54-fold with IL-1β in group 1, and decreased 
by 0.66-fold with TNF-α and 0.62-fold with IL-1β in group 
2. The response to rhBMP-2 and TGF-β in group 1 was 
greater by 1.84 times and 2.00 times than those in group 2, 
respectively (p<0.05). The response to others cytokines dem-
onstrated no statistical difference between the two groups 
(Fig. 2B).
The mRNA levels of type I collagen after treatment with 
Fig. 2. The mRNA levels of aggrecan (A), alkaline phosphatase (B), type I collagen (C), type II collagen (D), osteocalcin (E), and Sox9 (F) after treatment with 
morphogens. vs. no treatment; *p<0.01 and **p<0.05. Group 1 vs. group 2; ‡p<0.01 and †p<0.05. TGF-β, transforming growth factor-β; TNF-α, tumor necrosis 
factor-α; IL-1β, interleukin-1β; rhBMP-2, recombinant human bone morphogenic protein-2.
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respectively, in group 2. The average numbers of immuno-
fluorescence-positive-stained IVD cells for aggrecan in-
creased by 4.21 times with rhBMP-2 and 3.72 times with 
TGF-β in group 1, and increased by 2.14 times with rh-
BMP-2 and 1.94 times with TGF-β in group 2. The respons-
es to rhBMP-2 and TGF-β in group 1 were 1.96 times and 
1.92 times greater than those in group 2, respectively (p< 
0.05) (Table 2, Figs. 3 and 4).
For the control group (no treatment), rhBMP-2 100 ng/mL 
group, and TGF-β 10 ng/mL group, the average numbers of 
immunofluorescence-positive-stained IVD cells for alkaline 
phosphatase were 6.57×103, 2.45×104, and 2.41×104, respec-
tively, in group 1 and 4.86×103, 1.22×104, and 1.12×104, re-
spectively, in group 2. The average number of immunofluo-
rescence-positive-stained IVD cells for alkaline phosphatase 
increased 3.73 times with rhBMP-2 and 3.66 times with 
TGF-β in group 1, and increased 2.52 times with rhBMP-2 
and 2.29 times with TGF-β in group 2. The responses to rh-
BMP-2 and TGF-β in group 1 were 1.48 times and 1.59 
times greater than those in group 2, respectively (p<0.05).
For the control group (no treatment), rhBMP-2 treatment 
group, and TGF-β treatment group, the average numbers of 
immunofluorescence-positive-stained IVD cells for type I 
collagen were 6.50×103, 2.67×104, and 2.56×104, respec-
tively, in group 1, and 4.32×103, 7.92×103, and 8.69×103, 
respectively, in group 2. The average number of immuno-
fluorescence-positive-stained IVD cells for type I collagen 
increased 4.11 times with rhBMP-2 and 2.01 times with 
TGF-β in group 1, and increased 1.83 times with rhBMP-2 
and 1.95 times with TGF-β in group 2. The response to rh-
BMP-2 and TGF-β in group 1 were 2.24 times and 1.96 
times greater than those in group 2, respectively (p<0.05).
For the same three treatment groups above, the average 
numbers of immunofluorescence-positive-stained IVD cells 
for type II collagen were 6.98×103, 2.53×104, and 2.42×104, 
respectively, in group 1 and 6.21×103, 1.47×104, and 1.59× 
with inflammatory mediators decreased by 0.56-fold with 
TNF-α and 0.49-fold with IL-1β in group 1 and decreased 
by 0.67-fold with TNF-α and 0.67-fold with IL-1β in group 
2. Response to rhBMP-2 in group 1 was 1.55 times greater 
than that of group 2 (p<0.05). However, the response to 
others cytokines showed no statistical difference between 
the two groups (Fig. 2D).
The mRNA levels of osteocalcin after treatment with mor-
phogens increased by 4.83-fold with rhBMP-2 and 3.04-fold 
with TGF-β in group 1, and increased by 2.46-fold with rh-
BMP-2 and 1.77-fold with TGF-β in group 2. The mRNA 
expression for osteocalcin after treatment with inflammato-
ry mediators decreased by 0.52-fold with TNF-α and 0.65-
fold with IL-1β in group 1, and decreased by 0.76-fold with 
TNF-α and 0.67-fold with IL-1β in group 2. The response 
to TGF-β in group 1 was 1.72 times greater than that of 
group 2 (p<0.05). The response to others cytokines showed 
no statistical difference between the two groups (Fig. 2E).
The mRNA levels of Sox9 after treatment with morpho-
gens increased by 5.17-fold with rhBMP-2 and 3.69-fold 
with TGF-β in group 1 and increased by 2.44-fold with rh-
BMP-2 and 2.41-fold with TGF-β in group 2. The mRNA 
expression for Sox9 after treatment with inflammatory me-
diators decreased by 0.53-fold with TNF-α and 0.68-fold 
with IL-1β in group 1 and decreased by 0.64-fold with 
TNF-α and 0.68-fold with IL-1β in group 2. The response 
to TGF-β in group 1 was 1.72 times greater than that in 
group 2 (p<0.05). The response to others cytokines showed 
no statistical difference between the two groups (Fig. 2F).
Immunoreactivity of IVD for rhBMP-2 and TGF-β
The average numbers of immunofluorescence-positive-
stained IVD cells for aggrecan according to the control group 
(no treatment), rhBMP-2 100 ng/mL group and TGF-β 10 
ng/mL group, were 6.20×103, 2.61×104, and 2.31×104, re-
spectively, in group 1, and 5.04×103, 1.08×104, and 9.76×103, 
Table 2. Production Ratio of Immunofluorescence-Positive-Stained IVD Cells for rhBMP-2 and TGF-β
Group 1 Group 2 rhBMP-2
group 1/group 2
TGF-β
group 1/group 2rhBMP-2 TGF-β rhBMP-2 TGF-β
Aggrecan 4.21 3.72 2.14 1.96 1.96* 1.92*
Alkaline phosphatase 3.73 3.66 2.52 1.48 1.48* 1.59*
Type I collagen 4.11 2.01 1.83 2.24 2.24* 1.96*
Type II collagen 3.62 3.47 2.38 1.53 1.53* 1.35*
Osteocalcin 3.54 3.30 2.38 1.49 1.49* 1.68*
Sox9 4.19 3.85 2.25 1.86 1.86* 1.87*
IVD, intervertebral disc; rhBMP-2, recombinant human bone morphogenic protein-2; TGF-β, transforming growth factor-β.
*p<0.05.
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spectively, in group 1, and 5.58×103, 1.37×104, and 1.10×104, 
respectively, in group 2. The average number of immuno-
fluorescence-positive-stained IVD cells for osteocalcin in-
creased 3.54 times with rhBMP-2 and 3.30 times with 
TGF-β in group 1, and increased 2.38 times with rhBMP-2 
and 1.97 times with TGF-β in group 2. The responses to rh-
BMP-2 and TGF-β in group 1 were 1.49 times and 1.68 
times greater than those in group 2, respectively (p<0.05).
For the control group (no treatment), rhBMP-2 treatment 
group, and TGF-β treatment group, the average numbers of 
104, respectively, in group 2. The average number of immu-
nofluorescence-positive-stained IVD cells for type II colla-
gen increased 3.62 times with rhBMP-2 and 3.47 times with 
TGF-β in group 1, and increased 2.38 times with rhBMP-2 
and 2.56 times with TGF-β in group 2. The responses to rh-
BMP-2 and TGF-β in group 1 were 1.53 times and 1.35 
times greater than those in group 2, respectively (p<0.05).
The average numbers of immunofluorescence-positive-
stained IVD cells for osteocalcin in the three treatment 
groups above were 6.30×103, 2.23×104, and 2.08×104, re-
Fig. 3. Immunostaining of human IVD cells for aggrecan, alkaline phosphatase, type I collagen, type II collagen, osteocalcin, and Sox9 in 
group 1 (mild degenerative IVD) after rhBMP-2 and TGF-β treatment. IVD, intervertebral disc; rhBMP-2, recombinant human bone mor-
phogenic protein-2; TGF-β, transforming growth factor-β.
Fig. 4. Immunostaining of human IVD cells for aggrecan, alkaline phosphatase, type I collagen, type II collagen, osteocalcin, and Sox9 in 
group 2 (mild degenerative IVD) after rhBMP-2 and TGF-β treatment. IVD, intervertebral disc; rhBMP-2, recombinant human bone mor-
phogenic protein-2; TGF-β, transforming growth factor-β.
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phogenic cytokines and inflammatory mediators in this 
study. The comparative response to these four cytokines be-
tween group 1 (mild degenerative IVD) and group 2 (se-
vere degenerative IVD) were assayed in terms of gene and 
protein expression and a statistically significant difference 
was found. mRNA expression in mild degenerative IVD 
was significantly greater than that in severe degenerative 
IVDs for aggrecan, type I collagen, type II collagen, alkaline 
phosphatase, osteocalcin, and Sox9 before cytokine treat-
ment. After the treatment with morphogens, mRNA levels 
for these molecules increased significantly in both groups, 
the effects were much greater in group 1. There was no sig-
nificant difference between the groups after treatment with 
inflammatory cytokines, however. Micrographic analysis of 
rhBMP-2 and TGF-β immunoreactive IVD cells for aggre-
can, alkaline phosphatase, type I collagen, type II collagen, 
osteocalcin, and Sox9 revealed similar results in both groups. 
Differences in cell proliferation upon treatment with rh-
BMP-2, TGF-β, TNF-α, and IL-1β in degenerative living 
human IVDs may differ according to type of cytokine and 
inflammatory mediator.
The average number of immunofluorescence-positive-
stained IVD cells for alkaline phosphatase increased after 
treatment with rhBMP-2 and TGF-β in group 1. Microscopi-
cally, IVD cells showed strong immunoreactivity and well-
demarcated configuration. Our results highlights several fea-
tures: treatment with rhBMP-2 and TGF-β increases the 
expression of the various genes associated with matrix syn-
thesis, including aggrecan, alkaline phosphatase, type I colla-
gen, type II collagen, osteocalcin, and Sox9. Treatment with 
TNF-α and IL-1β decreases the expression of these genes. As 
separate treatment with rhBMP-2 or TGF-β showed signifi-
cant increases in mRNA expression and cell proliferation, a 
synergic effect may be expected after treatment with rh-
BMP-2 combined with TGF-β. The results of the mRNA 
expression and immunofluorescence study revealed that rh-
BMP-2 and TGF-β play a role in cell metabolism and pro-
liferation.
The molecular responses to treatment with rhBMP-2, 
TGF-β, TNF-α, and IL-1β in degenerative living human 
IVDs may differ according to the degree of IVD degenera-
tion. Even though IVD cells from mild degenerative IVD 
specimens in group 1 showed greater molecular response to 
treatment with cytokines than those from severe degenera-
tive IVD specimens in group 2 in this in vitro study, several 
factors should be considered when classifying IVD cells by 
degree of degeneration in living humans such as IVD cell 
immunofluorescence-positive-stained IVD cells for Sox9 
were 6.60×103, 2.77×104, and 2.54×104, respectively, in 
group 1 and 5.76×103, 1.29×104, and 1.19×104, respective-
ly, in group 2. The average number of immunofluores-
cence-positive-stained IVD cells for Sox9 increased 4.19 
times with rhBMP-2 and 3.85 times with TGF-β in group 
1, and increased 2.25 times with rhBMP-2 and 2.06 times 
with TGF-β in group 2. The responses to rhBMP-2 and 
TGF-β in group 1 were 1.86 times and 1.87 times greater 
than those in group 2, respectively (p<0.05).
DISCUSSION
Disc degenerative changes may be associated with pain, 
and treatment options for disc degeneration are limited. 
Among the various genes associated with matrix synthesis, 
type I and type II collagen act as fibrillar molecules; aggre-
can is a core protein for sulfated glycosaminoglycans, Sox9 
upregulates both aggrecan and type II collagen; and osteo-
calcin and alkaline phosphatase are markers of osteogenici-
ty.35-39 Proinflammatory cytokines, such as TNF-α and IL, 
are well known to be associated with disc degradation.5,40-42
With degeneration, IVDs show down regulation of vari-
ous genes for aggrecan, type II collagen, Sox9, type I colla-
gen, alkaline phosphatase, osteocalcin and others.5,38,40 Vari-
ous inflammatory mediators have also been implicated in 
the degeneration of the IVD and discogenic pain, including 
nitric oxide, ILs, matrix metalloproteinases, prostaglandin E2 
and a group of cytokines.25 TNF-α and IL-1β are well known 
to be associated with disc degradation and discogenic back 
pain.26,27,43 TNF-α is an important initiator of matrix degener-
ation, whereas IL-1β plays a greater role in pathological deg-
radation. 
Many growth factors, including IGF-1, TGF-1, BMP-2, 
and BMP-7 have been extensively investigated by the carti-
lage research community, and have been shown to positive-
ly influence the metabolism and healing potential of carti-
lage.18,44-46 With this success and the similar chondrocytic 
composition of IVDs, investigations into the effects of growth 
factors on IVD cells have been performed by researchers. 
All of these molecules have some in vitro data regarding 
their effects, although few have been tested in vivo in animal 
models of disc degeneration to verify the biological mecha-
nisms of each molecule. There is no clinically proven bio-
logical therapy for degeneration of human IVDs.
rhBMP-2, TGF-β, TNF-α, and IL-1β were used as mor-
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for changes in the biosynthesis and denaturation of the extracellu-
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7. Takegami K, Thonar EJ, An HS, Kamada H, Masuda K. Osteo-
genic protein-1 enhances matrix replenishment by intervertebral 
disc cells previously exposed to interleukin-1. Spine (Phila Pa 
1976) 2002;27:1318-25.
8. An HS, Takegami K, Kamada H, Nguyen CM, Thonar EJ, Singh 
K, et al. Intradiscal administration of osteogenic protein-1 increas-
es intervertebral disc height and proteoglycan content in the nucle-
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pulposus and annulus fibrosus cells to repair their matrix after 
chondroitinase ABC-induced in vitro chemonucleolysis. Spine J 
2005;5:231-8. 
10. Sakai D, Mochida J, Yamamoto Y, Nomura T, Okuma M, Nishimu-
ra K, et al. Transplantation of mesenchymal stem cells embedded in 
Atelocollagen gel to the intervertebral disc: a potential therapeutic 
model for disc degeneration. Biomaterials 2003;24:3531-41.
11. Watanabe K, Mochida J, Nomura T, Okuma M, Sakabe K, Seiki 
K. Effect of reinsertion of activated nucleus pulposus on disc de-
generation: an experimental study on various types of collagen in 
degenerative discs. Connect Tissue Res 2003;44:104-8.
12. Matsunaga S, Nagano S, Onishi T, Morimoto N, Suzuki S, Komi-
ya S. Age-related changes in expression of transforming growth 
factor-beta and receptors in cells of intervertebral discs. J Neuro-
surg 2003;98(1 Suppl):63-7.
13. Okuda S, Myoui A, Ariga K, Nakase T, Yonenobu K, Yoshikawa 
H. Mechanisms of age-related decline in insulin-like growth fac-
tor-I dependent proteoglycan synthesis in rat intervertebral disc 
cells. Spine (Phila Pa 1976) 2001;26:2421-6.
14. Osada R, Ohshima H, Ishihara H, Yudoh K, Sakai K, Matsui H, et 
al. Autocrine/paracrine mechanism of insulin-like growth factor-1 
secretion, and the effect of insulin-like growth factor-1 on proteo-
glycan synthesis in bovine intervertebral discs. J Orthop Res 1996; 
14:690-9.
15. Gruber HE, Hanley EN Jr. Biologic strategies for the therapy of 
intervertebral disc degeneration. Expert Opin Biol Ther 2003;3: 
1209-14.
16. Brisby H, Tao H, Ma DD, Diwan AD. Cell therapy for disc degen-
eration--potentials and pitfalls. Orthop Clin North Am 2004;35:85-
93.
17. Handa T, Ishihara H, Ohshima H, Osada R, Tsuji H, Obata K. Ef-
fects of hydrostatic pressure on matrix synthesis and matrix metal-
loproteinase production in the human lumbar intervertebral disc. 
Spine (Phila Pa 1976) 1997;22:1085-91.
18. Martinek V, Ueblacker P, Imhoff AB. Current concepts of gene 
count, the degree of hydration, elasticity, the existence of a 
vacuum disc, and intradiscal pressure. Therefore, the molec-
ular responses to treatment with rhBMP-2, TGF-β, TNF-α, 
and IL-1β in degenerative living human IVDs may differ in 
an in vivo study. 
Degeneration of the IVD is a complex process that dis-
rupts an otherwise well-defined organization and biochemi-
cal balance. Many different biological treatment modalities 
have been studied to treat degenerative disc disease. Some 
bioactive molecules have been investigated for clinical ap-
plications. However, most of the data for the biologic re-
sponsiveness of various genes and proteins related to disc 
degeneration upon treatment with cytokines that influence 
disc-cell metabolism and phenotype has been obtained us-
ing animal IVDs. However, experimental data for animal 
IVDs cannot be applied to clinical treatment. In the present 
study, treatment with rhBMP-2 and TGF-β modulated mo-
lecular responses in degenerative living human IVD cells, 
and the molecular responses differed according to the degree 
of IVD degeneration. Thus, the degree of IVD degeneration 
may be an important factor to the responsiveness of IVD 
cells to biologic therapies in clinical application. Neverthe-
less, while cytokine treatment may be effective in treating 
both severe degenerative IVD and mild degenerative IVD, 
the potential clinical use of rhBMP-2 and TGF-β for treat-
ment of degenerative IVD is limited due to their short biolog-
ic half-life. Chronic conditions like internal disc disruption 
(IDD) may require more prolonged and sustained cytokine 
levels in order to generate a therapeutic effect. This has led 
investigators to contemplate the potential use of gene thera-
py as a treatment modality.
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